68 results on '"Mamatha Chivukula"'
Search Results
2. Serous fluid: Metastatic sarcomas, melanoma, and other non-epithelial neoplasms
- Author
-
Liron, Pantanowitz and Mamatha, Chivukula
- Subjects
Pathology and Forensic Medicine - Abstract
While most tumors metastatic to the serous membranes are of epithelial origin, cytologists should be aware that non-epithelial neoplasms can also cause malignant effusions including sarcomas, melanomas, germ cell tumors, and, more rarely, brain tumors. The differential diagnosis of a malignant effusion is accordingly broad, especially for the small round blue cell tumors that includes not only mesenchymal tumors, but also non-mesenchymal tumors, such as neuroblastoma and Wilms tumor. Diagnosing non-epithelial malignancies in effusion specimens based entirely upon their cytomorphologic features is difficult because these neoplasms often exhibit considerable morphological overlap and their cytomorphology can differ from the original tumor. As malignant cells have a tendency to round up in body fluids these non-epithelial neoplasms can therefore mimic reactive mesothelial cells and metastatic adenocarcinoma. The use of ancillary studies including immunostaining, FISH, and molecular studies is thus often critical to reach a definitive diagnosis. This review article will be incorporated finally as one of the chapters in CMAS (CytoJournal Monograph/Atlas Series) #2. It is modified slightly from the chapter by the initial authors in the first edition of Diagnostic Cytopathology of Serous Fluids.
- Published
- 2022
3. HER2 testing across practices-Have we come to a consensus on the ideal method of testing? A systematic literature review
- Author
-
Advani Pooja, Mamatha Chivukula, and Aziza Nassar
- Subjects
Oncology ,Drug ,medicine.medical_specialty ,Consensus ,Receptor, ErbB-2 ,medicine.medical_treatment ,media_common.quotation_subject ,Breast Neoplasms ,Antibodies, Monoclonal, Humanized ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Trastuzumab ,Internal medicine ,Internal Medicine ,medicine ,Biomarkers, Tumor ,Humans ,skin and connective tissue diseases ,neoplasms ,In Situ Hybridization, Fluorescence ,media_common ,Chemotherapy ,medicine.diagnostic_test ,business.industry ,medicine.disease ,Systematic review ,030220 oncology & carcinogenesis ,Immunohistochemistry ,Surgery ,Female ,business ,Adjuvant ,Fluorescence in situ hybridization ,medicine.drug - Abstract
Human epidermal growth factor (HER2) is an oncogene that codes for HER2 protein. The gene is amplified, and protein is overexpressed in 20% of patients and carries a poor prognosis. HER2-positive tumors tend to be more aggressive and highly proliferative. In 2006, trastuzumab, a monoclonal antibody targeting HER2, was approved for use with chemotherapy as an adjuvant treatment for women with HER2-positive breast cancer. The drug has shown improved survival rates for women with HER2-positive breast cancer. As promised for survival in HER2-positive patients continues with new research, and as novel drug approvals emerge, HER2 assessment plays a significant role in adjuvant and in metastatic setting. HER2 assays approved by the US Food and Drug administration include immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and bright field dual in situ hybridization (DISH). Accuracy of HER2 testing across laboratories has an impact on treatment as false-negative testing can deprive the patients of trastuzumab therapy. The current review will focus on the variability of HER2 testing across laboratories and the potential impact on treatment.
- Published
- 2020
4. Interobserver Reproducibility Among Gynecologic Pathologists in Diagnosing Heterologous Osteosarcomatous Component in Gynecologic Tract Carcinosarcomas
- Author
-
Robert A. Soslow, Marisa R. Nucci, Andrew E. Horvai, Joseph T. Rabban, Andres A. Roma, Charles Zaloudek, Russell Vang, Jesse K. McKenney, Vinita Parkash, Charles M. Quick, Ankur R. Sangoi, Jacqueline Haas, Teri A. Longacre, Lora Hedrick Ellenson, Malti Kshirsagar, Anna Yemelyanova, Kay J. Park, W Glenn McCluggage, Ann K. Folkins, Andrew H. Beck, Joanne L. Rutgers, Krisztina Z. Hanley, Oluwole Fadare, Karuna Garg, Esther Oliva, and Mamatha Chivukula
- Subjects
musculoskeletal diseases ,0301 basic medicine ,Pathology ,medicine.medical_specialty ,Genital Neoplasms, Female ,Mixed Tumor, Mullerian ,Interobserver reproducibility ,Heterologous ,Sensitivity and Specificity ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Carcinosarcoma ,Biomarkers, Tumor ,Humans ,Medicine ,Medical diagnosis ,Observer Variation ,Osteosarcoma ,Mixed tumor ,business.industry ,Surrogate endpoint ,Osteoid ,Reproducibility of Results ,Obstetrics and Gynecology ,Matrix Attachment Region Binding Proteins ,Prognosis ,medicine.disease ,Pathologists ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,business ,Transcription Factors - Abstract
Distinguishing hyalinized stroma from osteoid production by a heterologous osteosarcomatous component can be challenging in gynecologic tract carcinosarcomas. As heterologous components in a carcinosarcoma may have prognostic and therapeutic implications, it is important that these are recognized. This study examines interobserver reproducibility among gynecologic pathologists in the diagnosis of osteosarcomatous components, and its correlation with expression of the novel antibody SATB2 (marker of osteoblastic differentiation) in these osteosarcomatous foci. Digital HE images from 20 gynecologic tract carcinosarcomas were reviewed by 22 gynecologic pathologists with a request to determine the presence or absence of an osteosarcomatous component. The 20 preselected cases included areas of classic heterologous osteosarcoma (malignant cells producing osteoid; n=10) and osteosarcoma mimics (malignant cells with admixed nonosteoid matrix; n=10). Interobserver agreement was evaluated and SATB2 scored on all 20 cases and compared with the original diagnoses. Moderate agreement (Fleiss' κ=0.483) was identified for the 22 raters scoring the 20 cases with a median sensitivity of 7/10 and a median specificity of 9/10 for the diagnosis of osteosarcoma. SATB2 showed 100% sensitivity (10/10) and 60% (6/10) specificity in discriminating classic osteosarcoma from osteosarcoma mimics. Utilizing negative SATB2 as a surrogate marker to exclude osteosarcoma, 73% (16/22) of the reviewers would have downgraded at least 1 case to not contain an osteosarcomatous component (range, 1-6 cases, median 1 case). Gynecologic pathologists demonstrate only a moderate level of agreement in the diagnosis of heterologous osteosarcoma based on morphologic grounds. In such instances, a negative SATB2 staining may assist in increasing accuracy in the diagnosis of an osteosarcomatous component.
- Published
- 2017
5. Special Clinical Settings: Tumors Arising in Pregnancy, Pregnancy-Like (Pseudolactational) Proliferations, Breast Carcinoma in the Pre-neoadjuvant Chemotherapy Setting, Recurrent Breast Carcinoma, and Inflammatory Breast Carcinoma
- Author
-
Paula S. Ginter, Sandra J. Shin, and Mamatha Chivukula
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,Pregnancy ,business.industry ,medicine.medical_treatment ,Clinical settings ,medicine.disease ,humanities ,Breast cancer ,Internal medicine ,medicine ,Breast disease ,skin and connective tissue diseases ,business ,Breast carcinoma ,Inflammatory Breast Carcinoma ,Recurrent Breast Carcinoma - Abstract
This chapter discusses special clinical scenarios that involve the evaluation of core needle biopsies. The topics covered in this chapter are breast disease in the setting of pregnancy and lactation as well as changes that resemble those seen in the pregnant state (pregnancy-like or pseudolactational), breast carcinoma in the neoadjuvant chemotherapy setting, recurrent breast carcinoma, and inflammatory breast carcinoma.
- Published
- 2016
6. Is PAX2 a Reliable Marker in Differentiating Diffuse Malignant Mesotheliomas of Peritoneum From Serous Carcinomas of Müllerian Origin?
- Author
-
Mamatha Chivukula, Alyssa M. Krasinskas, and Faye F. Gao
- Subjects
Mesothelioma ,Pathology ,medicine.medical_specialty ,Histology ,medicine.medical_treatment ,PAX2 ,Gene Expression ,Müllerian mimicry ,Pathology and Forensic Medicine ,Diagnosis, Differential ,Peritoneal cavity ,S100 Calcium Binding Protein G ,Peritoneum ,Biomarkers, Tumor ,medicine ,Humans ,WT1 Proteins ,Peritoneal Neoplasms ,Ovarian Neoplasms ,Chemotherapy ,business.industry ,Ovary ,PAX2 Transcription Factor ,Immunohistochemistry ,Cystadenocarcinoma, Serous ,Radiation therapy ,Medical Laboratory Technology ,Serous fluid ,medicine.anatomical_structure ,Calbindin 2 ,Female ,Calretinin ,business - Abstract
Diffuse peritoneal malignant mesotheliomas (DPMM) are often disseminated in the peritoneal cavity as multiple nodules including localized masses in the ovaries that are clinically and histologically similar to serous adenocarcinomas of müllerian origin. It is imperative to differentiate these tumors given their diverse responses to chemotherapy and/or radiotherapy. PAX2 gene was recently demonstrated in benign epithelial cells of the female genital tract and in serous carcinomas (SC) of müllerian origin. The aim of our study was to determine if PAX2 can reliably be used in differentiating DPMM from SC. A total of 59 cases to include 25 cases of DPMM and 34 cases of SC were retrieved. All cases were stained with PAX2, Wilm tumor gene 1, calretinin and the results were compared. Our results demonstrate that PAX2 can be used reliably as a Müllerian marker in formulating an efficient panel to differentiate DPMM and SC.
- Published
- 2012
7. Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients
- Author
-
Roslyn A. Stone, Joel L. Weissfeld, Robert P. Edwards, Mamatha Chivukula, Ashley S. Felix, Faina Linkov, Anil V. Parwani, and Robert Bowser
- Subjects
Cancer Research ,medicine.medical_specialty ,Disease free survival ,C-Met ,Angiogenesis ,Basic fibroblast growth factor ,Biology ,prognostic biomarkers ,Disease-Free Survival ,03 medical and health sciences ,chemistry.chemical_compound ,angiogenesis ,0302 clinical medicine ,Stroma ,Internal medicine ,Recurrence free survival ,Cell Line, Tumor ,growth factors ,medicine ,stroma ,Biomarkers, Tumor ,Humans ,recurrence-free survival ,Molecular Diagnostics ,030304 developmental biology ,Aged ,0303 health sciences ,Hepatocyte Growth Factor ,Endometrial cancer ,Middle Aged ,medicine.disease ,Prognosis ,3. Good health ,Endometrial Neoplasms ,Endocrinology ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Cancer research ,Hepatocyte growth factor ,Female ,Fibroblast Growth Factor 2 ,medicine.drug - Abstract
Background: Hepatocyte growth factor (HGF), c-Met, and basic fibroblast growth factor (bFGF) are molecular markers that contribute to angiogenesis and proliferation in numerous cancers. We assessed the prognostic significance of these factors in tumour and stroma of endometrial cancer (EC) patients (n=211). Methods: Immunohistochemistry (IHC) was used to detect tumour and stromal protein expression of the biomarkers. Associations between expression and clinicopathological factors were assessed using Chi-square tests. Kaplan–Meier curves, log-rank tests, and Cox regression were used to summarise associations between biomarker expression and overall survival (OS) and recurrence-free survival (RFS). Results: Tumour bFGF was significantly associated with high-grade endometrioid and clear cell histology (P
- Published
- 2012
8. Carcinomas of Distal Fallopian Tube and Their Association with Tubal Intraepithelial Carcinoma: Do They Share a Common 'Precursor' Lesion? Loss of Heterozygosity and Immunohistochemical Analysis Using PAX 2, WT-1, and P53 Markers
- Author
-
Kim McManus, Robert P. Edwards, Marina N. Nikiforova, Leo A. Niemeier, Mamatha Chivukula, Gloria Carter, and Geetha Mantha
- Subjects
Pathology ,medicine.medical_specialty ,animal structures ,Article Subject ,urogenital system ,business.industry ,Precursor lesion ,PAX2 ,medicine.disease_cause ,female genital diseases and pregnancy complications ,body regions ,Loss of heterozygosity ,Serous fluid ,Tubal Intraepithelial Carcinoma ,medicine.anatomical_structure ,medicine ,Immunohistochemistry ,business ,Carcinogenesis ,Research Article ,Fallopian tube - Abstract
As the role of distal fallopian tube as organ of serous carcinogenesis is emerging, additional literature on the role of tubal intraepithelial carcinoma (TIC) as a precursor lesion in a subset of primary peritoneal serous carcinomas (PPSC is emerging as well. TIC although fallopian tube in origin can be genetically related to ovarian/peritoneal carcinomas. The role of PAX2 in primary fallopian tube carcinomas (PFTC)/PPSC is yet to be defined. The aim of our study was to understand if the biologic properties of tumors arising in the distal fallopian tube that remain as PFTC are different when they seed on to the peritoneal surface (PPSC). A panel of 6 polymorphic microsatellite markers corresponding to p53, PAX2, and WT1 tumor suppressor genes were studied. Invasive carcinomas as well as TIC arising in the distal fallopian tube when remain as PFTC appears to exhibit different LOH patterns in comparison to PPSC. PAX 2 LOH patterns might represent a “hidden PAX 2 signature” analogous to p53 signatures. PAX 2 might be an emerging marker for detection of early serous carcinomas particularly in BRCA + women.
- Published
- 2011
9. An Immunohistochemical Panel to Differentiate Metastatic Breast Carcinoma to Skin From Primary Sweat Gland Carcinomas With a Review of the Literature
- Author
-
David J. Dabbs, Marian A. Rollins-Raval, Drazen M. Jukic, Mamatha Chivukula, and George C. Tseng
- Subjects
Adult ,Pathology ,medicine.medical_specialty ,Skin Neoplasms ,Breast Neoplasms ,Pathology and Forensic Medicine ,Diagnosis, Differential ,Breast cancer ,Predictive Value of Tests ,Sweat gland ,Biomarkers, Tumor ,Carcinoma ,Humans ,Medicine ,Aged ,Aged, 80 and over ,business.industry ,Carcinoma, Ductal, Breast ,General Medicine ,Middle Aged ,Metastatic Breast Carcinoma ,medicine.disease ,Immunohistochemistry ,Sweat Gland Neoplasms ,Medical Laboratory Technology ,medicine.anatomical_structure ,Female ,business - Abstract
Context.—Approximately 25% of patients with breast cancer develop cutaneous metastases. Sweat gland carcinomas (SGCs) account for about 0.05% of all cutaneous neoplasms. Cutaneous metastases of breast carcinoma (CMBCs) (especially the ductal type) can be difficult to distinguish from SGCs. Treatment and prognoses for these 2 types of tumors differ radically, making accurate histologic diagnosis crucial. Although a few studies attempt to differentiate these entities employing immunohistochemical (IHC) studies (some of which we review here), to date, no panel of IHC stains exists, to our knowledge, to distinguish these entities. Objective.—To devise a panel of IHC stains to distinguish CMBC from SGC. Design.—Twelve cases of ductal CMBCs (11 not otherwise specified type, and 1 basal phenotype), 11 cases of SGCs (5 eccrine carcinomas, 3 porocarcinomas, and 3 microcystic adnexal carcinomas), 2 benign sweat gland neoplasm cases, and 2 primary breast cancer cases were retrieved and analyzed with the following IHC panel: mammaglobin, gross cystic disease fluid protein (GCDFP) 15, p63, basal cytokeratins (CK5, CK14, and CK17), androgen receptor, and PAX5. Results.—The p63 was only weakly expressed in 1 of 12 CMBC cases (8.3%), whereas it was strongly expressed in 10 of 11 SGC cases (90.9%) (P < .001). Basal cytokeratins demonstrated a similar immunoprofile in the SGC group, with 10 of 11 cases (90.9%) expressing all 3 markers, and a variable immunoprofile in the CMBC group with 0% (CK14) (P < .001) to 16.7% (2 of 12 cases; CK5 and CK17) (P < .001) expression. Mammaglobin was expressed in 8 of 12 cases (66.7%) of CMBC. Conclusions.—Together, these 5 IHC stains were combined to make a panel that was 100% sensitive and 91% specific in distinguishing between CMBC and SGC.
- Published
- 2011
10. Comparison of Survival Outcomes Between Patients With Malignant Mixed Mullerian Tumors and High-Grade Endometrioid, Clear Cell, and Papillary Serous Endometrial Cancers
- Author
-
Robert P. Edwards, Joel L. Weissfeld, Robert Bowser, Ashley S. Felix, Mamatha Chivukula, Roslyn A. Stone, and Faina Linkov
- Subjects
Oncology ,medicine.medical_specialty ,Pathology ,Mixed Tumor, Mullerian ,Article ,Metastasis ,Cohort Studies ,Internal medicine ,Carcinosarcoma ,medicine ,Carcinoma ,Humans ,Cystadenocarcinoma ,Aged ,Retrospective Studies ,Mixed tumor ,Uterine sarcoma ,business.industry ,Endometrial cancer ,Obstetrics and Gynecology ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Carcinoma, Papillary ,Cystadenocarcinoma, Serous ,Endometrial Neoplasms ,Adenocarcinoma ,Female ,Neoplasm Grading ,business ,Carcinoma, Endometrioid ,Adenocarcinoma, Clear Cell - Abstract
Malignant mixed mullerian tumors (MMMTs) are an aggressive form of endometrial cancer (EC) with malignant epithelial and stromal components. Although MMMTs comprise less than 5% of ECs, 5-year overall survival (OS) rates for this subtype are extremely low, ranging from 20% to 35%.1–7 In comparison, low-grade endometrioid (EM) ECs have a 5-year OS rate approaching 90%.8 The significant morbidities associated with the MMMT subtype (ie, local and distant recurrences) represent challenges in the management of this invasive malignancy. Between 33% and 55% of MMMT cases have recurrence within 2 years of diagnosis.7,9 Studies that examine the MMMT subtype exclusively report that extent of the tumor, intraperitoneal metastasis, lymph node involvement, age, race, and stage predict recurrence and death.7,10–16 In the 1988 International Federation of Gynecology and Obstetrics (FIGO) staging criteria, MMMTs were grouped as uterine sarcomas owing to the presence of a sarcomatous component and poor survival in comparison to epithelial-derived EC. Consequently, MMMTs were excluded from FIGO staging.17 Pathologically, several theories of MMMT histogenesis exist; the most commonly accepted hypothesis is that most MMMTs are monoclonal, that is, derived from a single stem cell.18 The sarcomatous component of the tumor is derived either from the carcinoma during the progression of the tumor or from divergent differentiation of the 2 components from the same stem cell that occurs early in the development of the tumor.18 Evidence from Silverberg19 and Nordal13 suggests that the malignant epithelial component of MMMTs drives the aggressive behavior of this tumor. Malignant mixed mullerian tumors with a papillary serous (PS) or clear cell (CC) carcinomatous elements had a greater tendency for distant metastasis and poor survival compared to a low-grade EM element. Furthermore, MMMTs tend to metastasize via the lymphatic system, similar to the pattern of spread in epithelial EC subtypes. In contrast, 2 uterine sarcoma subtypes, leiyomyosarcomas and endometrial stromal sarcomas, metastasize primarily through the hematogenous route.20 Malignant mixed mullerian tumors share epidemiologic risk factors with EM-type ECs, including increasing weight, estrogen replacement therapy, and nulliparity.21,22 Based on this evidence, the most recent revision of the FIGO staging guidelines concluded that MMMTs should be staged as epithelial EC.23,24 Three studies have examined survival differences between MMMT and high-grade EM, CC, and PS EC patients.25–27 Similar to MMMTs, these epithelial subtypes are less common and associated with poor outcomes. The purpose of these studies was to discern whether MMMTs should be incorporated into clinical treatment trials with these other high-risk subtypes. Collectively, evidence from these studies suggests that MMMTs have significantly worse OS compared to high-risk epithelial subtypes and should not be included with these subtypes. Although advanced stage is associated with poor prognosis in MMMTs, shorter OS times have been observed in patients with MMMTs confined to the uterus.26,27 In adjusted Cox regression models, MMMTs had worse OS compared to non-EM cases (CC and PS subtypes combined) adjusted for stage27 and worse OS and RFS than high-grade EM cases adjusted for stage and vascular invasion.25 Although valuable, these studies are limited by small sample sizes and lack of control for important prognostic factors in survival outcomes. Our primary goals were to confirm or challenge the findings from previous studies, assess survival endpoints, and examine possible effect modification between histologic subtype and prognostic factors.
- Published
- 2011
11. Ductal Carcinoma in Situ: One Size does Not Fit All
- Author
-
Gretchen M. Ahrendt and Mamatha Chivukula
- Subjects
Oncology ,medicine.medical_specialty ,education.field_of_study ,business.industry ,medicine.medical_treatment ,Lumpectomy ,Population ,Estrogen receptor ,Cancer ,Articles ,General Medicine ,Ductal carcinoma ,medicine.disease ,Internal medicine ,Cohort ,Progesterone receptor ,medicine ,Biomarker (medicine) ,business ,education - Abstract
Evaluation of: Kerlikowske K, Molinaro AM, Gauthier ML et al.: Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J. Natl Cancer Inst. 102(9), 627–637 (2010). In a population-based case–control study cohort of 1162 women who were diagnosed with ductal carcinoma in situ (DCIS) and treated by lumpectomy alone from 1983 to 1994, a comprehensive analysis of biomarkers including estrogen receptor, progesterone receptor, p53, Her2/neu, p16, Ki67 and COX-2 in a selected cohort of 329 women was performed. Overall, patients presenting with palpable DCIS and patients who were triple positive for p16, COX-2 and Ki67 were found on multivariate analysis to have a significantly increased risk of subsequent invasive carcinoma. Neither nuclear grade nor histopathologic characteristics were associated with subsequent invasive carcinoma. Recurrent DCIS was associated with disease extent of 10 mm or more, positive resection margins, high nuclear grade, extensive necrosis and also associated with the biomarker combinations.
- Published
- 2010
12. PAX 2: A Novel Müllerian Marker for Serous Papillary Carcinomas to Differentiate From Micropapillary Breast Carcinoma
- Author
-
David J. Dabbs, Mamatha Chivukula, Rohit Bhargava, and Siobhan Marie O'Connor
- Subjects
Pathology ,medicine.medical_specialty ,endocrine system diseases ,Serous carcinoma ,Breast Neoplasms ,Pathology and Forensic Medicine ,Metastasis ,Diagnosis, Differential ,Breast cancer ,Biomarkers, Tumor ,medicine ,Carcinoma ,Humans ,Ovarian Neoplasms ,business.industry ,PAX2 Transcription Factor ,Obstetrics and Gynecology ,Ductal carcinoma ,medicine.disease ,female genital diseases and pregnancy complications ,Cystadenocarcinoma, Serous ,Serous fluid ,Tissue Array Analysis ,Cystadenocarcinoma, Papillary ,Female ,Breast disease ,business ,Breast carcinoma - Abstract
Ovarian serous papillary carcinoma, although rarely metastasizing to the breast, is often challenging based on morphology alone, particularly from the micropapillary variant of breast carcinoma. Gross cystic disease fluid protein-15, although a specific marker, can be negative in up to 50% of breast carcinomas. Wilm's tumor gene 1 (WT-1) has been identified as a useful marker to differentiate metastatic ovarian serous papillary carcinoma from primary breast carcinoma; however, it has recently been shown in the micropapillary variant of the primary breast carcinoma making it a less specific marker. PAX 2, a nuclear transcription factor, was recently observed in ovarian serous papillary carcinomas. In this study of 89 breast carcinoma cases, 26 micropapillary carcinoma, and 63 nonmicropapillary carcinoma types were retrieved from our pathology archives, represented on a single tissue microarray (TMA) with a 3-fold redundancy (TMA-1, TMA-2). In addition, whole tissue sections of a variety of benign and neoplastic müllerian tissues were surveyed with the PAX 2 immunostain. All cases were stained with rabbit polyclonal PAX 2 antibody and, in addition, the 5 metastatic ovarian serous carcinoma cases were stained with WT-1 as well for comparison. Only nuclear staining was considered positive. All primary breast carcinomas represented on TMA-1 and TMA-2 were entirely negative for PAX 2 100% (89/89), whereas 100% (5/5) of all metastatic ovarian serous carcinomas showed moderate-to-strong staining. PAX 2 expression was comparable with WT-1 as well in the metastatic ovarian serous carcinoma group. We therefore conclude that PAX 2 is a promising new, sensitive, and specific müllerian immunomarker for ovarian serous carcinomas (primary and metastatic).
- Published
- 2009
13. Basal-Like Subtype Breast Cancers in Women Older Than 40 Years of Age
- Author
-
Rohit Bhargava, Mamatha Chivukula, Çağatay Erşahin, and David J. Dabbs
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,DNA Mutational Analysis ,Genes, BRCA2 ,Population ,Genes, BRCA1 ,Breast Neoplasms ,Nerve Tissue Proteins ,Receptors, Nerve Growth Factor ,Tumor heterogeneity ,Pathology and Forensic Medicine ,Basal (phylogenetics) ,Breast cancer ,Internal medicine ,Biomarkers, Tumor ,medicine ,Carcinoma ,Humans ,education ,Aged ,Aged, 80 and over ,Basal-like carcinoma ,education.field_of_study ,business.industry ,Carcinoma, Ductal, Breast ,Myoepithelial cell ,Cancer ,DNA, Neoplasm ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Carcinoma, Intraductal, Noninfiltrating ,Keratins ,Female ,Surgery ,Anatomy ,business - Abstract
Basal-like (BL) carcinoma, distinguished by the expression of keratins that are a characteristic of myoepithelial cells, is 1 of the 5 distinct subtypes of breast tumors identified by gene microarray technologies. BL cancers have been well described in women 40 years of age were evaluated. The study demonstrated that there is a subset of patients >40 years of age with breast cancers, manifesting features of BL carcinoma. There has been a significant increase in BL cancers among women >40 years of age having larger tumors and lymph node metastasis in comparison with younger women
- Published
- 2009
14. Evaluation of Morphologic Features to Identify 'Basal-like Phenotype' on Core Needle Biopsies of Breast
- Author
-
Joan M. Striebel, Çağatay Erşahin, David J. Dabbs, and Mamatha Chivukula
- Subjects
Pathology ,medicine.medical_specialty ,Histology ,medicine.diagnostic_test ,business.industry ,Lymphovascular invasion ,Biopsy, Needle ,Breast Neoplasms ,Ductal carcinoma ,medicine.disease ,Pathology and Forensic Medicine ,Lymphocytic Infiltrate ,Medical Laboratory Technology ,Phenotype ,Immunophenotyping ,Carcinoma, Basal Cell ,Biopsy ,Carcinoma ,medicine ,Humans ,Immunohistochemistry ,Breast ,Breast carcinoma ,business ,Retrospective Studies - Abstract
The basal-like phenotype (BLP) subtype of breast carcinoma has been identified as 1 of 5 tumor subtypes first revealed by microarray profiling. This phenotype tends to be more aggressive, is more often associated with BRCA1 mutations, and carries a poor prognosis. Few studies have morphologically characterized BLP on resected breast specimens (RS), and no studies have evaluated these diagnostic parameters in core needle biopsies (CNB) of breast. We identified a group of 35 RS that demonstrated BLP by morphology and/or immunophenotype based on the criteria used in the literature. Retrospectively, we reviewed the CNB of these RS for the following morphologic features: growth pattern, nuclear grade, mitotic rate, presence of ductal carcinoma in situ, necrosis, and lymphocytic response. Of these histologic features, solid growth pattern [88.6% (31/35)] with nuclear grade 3 [100% (35/35)], marked lymphocytic infiltrate [74.3% (26/35)], and absence or
- Published
- 2008
15. Frequency and Clinical Significance of Simultaneous Association of Lobular Neoplasia and Columnar Cell Alterations in Breast Tissue Specimens
- Author
-
Gloria Carter, David J. Dabbs, Rouzan G. Karabakhtsian, A. M. Carley, and Mamatha Chivukula
- Subjects
Pathology ,medicine.medical_specialty ,Hyperplasia ,medicine.diagnostic_test ,business.industry ,Breast imaging ,Biopsy ,Lobular carcinoma ,Cancer ,Breast Neoplasms ,General Medicine ,medicine.disease ,Neoplasms, Multiple Primary ,Carcinoma, Lobular ,Carcinoma ,Humans ,Medicine ,Female ,Breast ,Breast carcinoma ,business ,Carcinoma in Situ ,Lobular Neoplasia - Abstract
Lobular neoplasia (LN) and columnar cell alterations (CCAs) may share similar genetic abnormalities, but there is no appreciable literature that addresses the simultaneous occurrence of these lesions in breast core biopsy (CNB) specimens or resection specimens. Three groups of breast tissue were examined: group 1, 68 CNB specimens targeted for "suspicious" microcalcifications (Breast Imaging Reporting and Data System [BI-RADS] 4) and diagnosed with LN; group 2, 2,516 CNB reports for a 1-year period; and group 3, 400 consecutive breast carcinoma resection specimens analyzed for LN and CCAs within the vicinity of carcinoma. In group 1, LN was associated with CCAs in 54% of cases (37/68). In group 2, LN was found in association with CCA in 1.3% of cases (32/2,516). In group 3, 13.0% of cases of CCAs (52/400) were associated with LN. Our study suggests the association of these two lesions in breast tissue is nonrandom and that they may have a common progenitor pathway of neoplastic development.
- Published
- 2008
16. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases
- Author
-
Urvashi Surti, Rohit Bhargava, David J. Dabbs, Adam Brufsky, and Mamatha Chivukula
- Subjects
Core needle ,Pathology ,medicine.medical_specialty ,Receptor, ErbB-2 ,Breast Neoplasms ,Sensitivity and Specificity ,Pathology and Forensic Medicine ,Resection ,Humans ,Medicine ,Clinical significance ,In Situ Hybridization, Fluorescence ,medicine.diagnostic_test ,business.industry ,Biopsy, Needle ,Carcinoma, Ductal, Breast ,Gene Amplification ,Genes, erbB-2 ,Immunohistochemistry ,Staining ,Female ,business ,Breast carcinoma ,Immunostaining ,Fluorescence in situ hybridization - Abstract
HER2 oncoprotein is overexpressed in 15-20% of breast carcinomas and is associated with poor outcome. The 2+ group is considered equivocal, since gene amplification is observed in some but not others. The aim of our study is to ascertain if there is clinical significance to heterogeneity of HER2 immunohistologic expression in breast core-needle biopsies vs surgical resection specimens. A total of 37 invasive breast carcinomas diagnosed on core-needle biopsies and scored 2+ by HER2 immunohistochemical assay were selected from our files. The results were obtained on these selected cases, of which 19 cases were nonamplified and 18 cases were amplified. The follow-up resection specimens were reviewed and two additional tumor blocks were selected in each case for HER2 immunostaining. The 74 tissue blocks were examined for HER2 using antibody clone CB11 on the Benchmark XT and scored as negative (score 0 or 1+), weakly positive (2+) or strongly positive (3+). Results within the amplified group, 56% (11/18) showed significant areas with 3+ score in both blocks, 28% (5/18) remained as 2+, 11% (2/18) showed score 0-1+. In the nonamplified group, 42% (8/19) had score 0-1+, 37% (7/19) remained as 2+, 0% (0/19) had score 3+. Five (5) cases showed heterogeneous staining in both the groups. In the amplified group, 56% of cases showed strong 3+ in both the blocks of which half of these cases had areas of 2+. Fluorescence in situ hybridization was performed on a representative resection specimen block. In the amplified group 72% (13/18) cases were amplified, 22% (4/18) were nonamplified. In the nonamplified group, no amplification is detected in a great majority of cases 89% (17/19). HER2 immunohistochemistry on core-needle biopsies is usually predictive of tumor HER2 status. However, performing fluorescence in situ hybridization on core-needle biopsies almost completely resolves the issue of heterogeneous expression of HER2.
- Published
- 2008
17. The Spectrum of Morphomolecular Abnormalities of the E-Cadherin/Catenin Complex in Pleomorphic Lobular Carcinoma of the Breast
- Author
-
Gloria Carter, Anisa Kanbour, David J. Dabbs, Amal Kanbour-Shakir, Mamatha Chivukula, and Malathy Kaplai
- Subjects
Pathology ,medicine.medical_specialty ,Histology ,Beta-catenin ,Lobular carcinoma ,Breast Neoplasms ,Biology ,Pathology and Forensic Medicine ,medicine ,Humans ,Neoplasm Invasiveness ,Breast ,skin and connective tissue diseases ,Cadherin ,Catenins ,Cadherins ,Prognosis ,medicine.disease ,Actin cytoskeleton ,body regions ,Carcinoma, Lobular ,Medical Laboratory Technology ,Catenin ,biology.protein ,Female ,Catenin complex ,Immunostaining ,Lobular Neoplasia - Abstract
Pleomorphic lobular carcinoma of the breast is a high nuclear grade variant of lobular carcinoma. E-cadherin, a tumor-invasion suppressor gene, codes for a transmembrane protein that functions in intercellular adhesion. The E-cadherin protein internal domain binds with alpha, beta, gamma, and p120 catenins to anchor the E-cadherin complex to the actin cytoskeleton of the cell. The E-cadherin gene is routinely mutated in lobular neoplasia. This study examines the morphomolecular spectrum of the components of the E-cadherin-catenin complex in lobular neoplasia. Fifteen cases of pleomorphic lobular neoplasia, 8 cases of classic lobular neoplasia and 4 ductal carcinomas were studied. Normal breast epithelium and invasive ductal carcinomas all showed intense linear cell membrane immunostaining with antibodies to E-cadherin, alpha, beta, gamma, and P120 catenins. Membrane immunostaining of the catenin antibodies in lobular neoplasia was negative, except for rare cases that displayed beaded or dotlike patterns. Cytoplasmic immunostaining patterns for all lobular lesions included coarse paranuclear granules of beta catenin or diffuse intense cytoplasmic staining for P120 catenin. These immunostaining patterns demonstrate that catenins alpha, beta, gamma, and p120 are routinely dislocated from the cell membrane into the cytoplasm in lobular neoplasia and that the disrupted catenin patterns parallel absence of membrane E-cadherin in all cases. The diffuse cytoplasmic immunostaining of p120 in lobular neoplasia may be useful diagnostically as a positive marker for lobular neoplasia.
- Published
- 2007
18. Recurrent Gynandroblastoma of Ovary-A Case Report
- Author
-
Jennifer L. Hunt, Amal Kanbour-Shakir, Gloria Carter, Minita Patel, Mamatha Chivukula, and Joseph L. Kelley
- Subjects
Adult ,endocrine system ,Pathology ,medicine.medical_specialty ,Stromal cell ,Granulosa cell ,CD99 ,Vimentin ,Biology ,Pathology and Forensic Medicine ,Cytokeratin ,Ovarian tumor ,Recurrence ,medicine ,Humans ,Sex Cord-Gonadal Stromal Tumors ,Neoplasm Staging ,Ovarian Neoplasms ,Obstetrics and Gynecology ,Sertoli cell ,Immunohistochemistry ,medicine.anatomical_structure ,biology.protein ,Female ,Follow-Up Studies - Abstract
Gynandroblastoma is a rare ovarian tumor that is composed of both Sertoli cells and granulosa cells. Only 23 cases have been reported in the literature, and recurrence has never been described. We report the first case of a recurrent gynandroblastoma along with its molecular analysis and immunohistochemical studies. A 49-year-old Gravida 0 woman with a 10-year prior diagnosis of ovarian-mixed stromal tissue tumor (well-differentiated Sertoli cell and granulosa cell tumor) and staging laparotomy, presented now with a retroperitoneal mass and an elevated inhibin level. CT scan was suspicious for recurrence. The patient had no prior adjuvant therapy. The histomorphological features of the recurrent tumor had both Sertoli cell and granulosa cell tumor. The molecular analysis of both primary and recurrent tumor showed minor genetic instability in the 17q12.2 gene locus with no dedifferentiation or progression, which is consistent with a low-grade tumor. The immunohistochemical staining profile showed positivity for CD99, inhibin, calretinin, and vimentin; focal positivity for cytokeratin AE1/AE3 and negative for EMA and melan-A. All the previously mentioned immunostainings support the diagnosis. We report the first case of a recurrent gynandroblastoma 10 years after initial presentation along with its molecular analysis and immunohistochemical studies.
- Published
- 2007
19. Novel HER2 dual in situ hybridization (DISH): technique and implementation in routine laboratory testing
- Author
-
Mamatha, Chivukula and Gautam, Bulusu
- Subjects
Diagnostic Tests, Routine ,Humans ,Genes, erbB-2 ,In Situ Hybridization - Published
- 2015
20. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile
- Author
-
David J. Dabbs, Gloria Carter, Rohit Bhargava, and Mamatha Chivukula
- Subjects
Adult ,Pathology ,medicine.medical_specialty ,Receptor, ErbB-2 ,Breast Neoplasms ,Vimentin ,Biology ,Pathology and Forensic Medicine ,Necrosis ,Immunophenotyping ,Biomarkers, Tumor ,medicine ,Carcinoma ,Humans ,Neoplasm Invasiveness ,Keratin-17 ,Tumor Suppressor Proteins ,Carcinoma, Ductal, Breast ,Keratin-14 ,Keratin-6 ,Myoepithelial cell ,Histology ,Ductal carcinoma ,medicine.disease ,Immunohistochemistry ,Actins ,DNA-Binding Proteins ,ErbB Receptors ,Proto-Oncogene Proteins c-kit ,Carcinoma, Intraductal, Noninfiltrating ,Phenotype ,Receptors, Estrogen ,Trans-Activators ,biology.protein ,Keratin-5 ,Female ,Receptors, Progesterone ,Breast carcinoma ,Transcription Factors - Abstract
The basal phenotype of breast carcinoma was demonstrated from a study of gene expression profiles, which demonstrated five carcinoma phenotypes with differing immunohistologic profiles and outcomes. The basal phenotype, so-named because of an immunohistologic profile that is similar to myoepithelial cells of the breast, has poor outcomes. While the invasive basal phenotype has been described, there is a paucity of literature regarding the existence or recognition of a precursor lesion. We searched our CoPath database for breast carcinomas in the age group of 37 years or less, and this yielded 98 cases from the years 2001 to April 2006. Pathology reports were screened for those cases that were negative for estrogen and progesterone receptors and HER-2/neu (triple negative). A total of 16 cases (16/98, 16%) fulfilled these criteria. Histology was reviewed and immunostains were performed for Cytokeratins 14, 17, and 5/6, vimentin, EGFR, c-kit, smooth muscle actin and p63. All 16 cases had a high-grade invasive ductal carcinoma, Nottingham score 9/9, with geographic necrosis, good circumscription and lymphoid infiltrates. Of the 16 cases, 13 exhibited at least one area of ductal carcinoma in situ (DCIS). The DCIS types were solid, flat or micropapillary, high nuclear grade, with comedonecrosis and invariably associated with intense lymphoid inflammatory cell infiltration. Of 16 invasive cases, 14 (88%) were positive for CK14, CK17, CK5/6 and EGFR; 94% were vimentin positive, while half or less of cases were positive for smooth muscle actin, c-kit or p63. All of the DCIS components demonstrated the same immunohistologic profile as the invasive component. A DCIS component of solid, flat or micropapillary type exists in the basal phenotype of breast carcinoma, and it demonstrates the same immunophenotype as the invasive carcinoma, typically positive for CK5/6, CK14, CK17, vimentin and EGFR, but negative for ER/PR and HER-2/neu.
- Published
- 2006
21. Shidham’s Staining Method: Evaluating Water-Soluble Crystals in Tissue Sections
- Author
-
Mamatha Chivukula and R. Nagarjun Rao
- Subjects
Pathology ,medicine.medical_specialty ,Tissue sections ,Water soluble ,Chemistry ,Biochemistry (medical) ,Clinical Biochemistry ,medicine ,Staining - Published
- 2002
22. Diagnostic, Theranostic, and Genomic Immunohistochemistry: Standardization Issues
- Author
-
Rohit Bhargava, Mamatha Chivukula, and David J. Dabbs
- Subjects
Pathology ,medicine.medical_specialty ,Standardization ,business.industry ,Immunohistochemistry ,Medicine ,Anatomy ,business ,Pathology and Forensic Medicine - Published
- 2008
23. Pleuropulmonary Metastasis of Glioblastoma Multiforme
- Author
-
Julie A. Biller, H. Erhan Dincer, Mamatha Chivukula, Hendrikus G. Krouwer, Grant Sinson, and Vinod B. Shidham
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Pleural effusion ,business.industry ,Internal medicine ,medicine ,Critical Care and Intensive Care Medicine ,medicine.disease ,business ,Glioblastoma ,Metastasis - Published
- 2006
24. Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma
- Author
-
Mirka W. Jones, David J. Dabbs, Mamatha Chivukula, David Cohen, Milon Amin, Kristine L. Cooper, Rohit Bhargava, Giuliana Trucco, and Terrell E Jones
- Subjects
Oncology ,medicine.medical_specialty ,Intraclass correlation ,Estrogen receptor ,Breast Neoplasms ,Breast cancer ,Internal medicine ,Progesterone receptor ,Medicine ,Humans ,Gynecology ,Observer Variation ,business.industry ,Carcinoma ,Carcinoma, Ductal, Breast ,Reproducibility of Results ,Anatomical pathology ,General Medicine ,medicine.disease ,Immunohistochemistry ,Confidence interval ,Receptors, Estrogen ,Hormone receptor ,Female ,Breast disease ,business ,Receptors, Progesterone - Abstract
The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines recommend reporting of hormone receptor test results in a semiquantitative manner. This study used 74 resected estrogen receptor (ER)–positive invasive breast cancers to determine reproducibility of semiquantitative scoring of hormone receptors using the H-score method. Four pathologists independently scored each slide. Agreement among observers was analyzed via Fleiss κ statistics on ER and progesterone receptor (PR) categorical scores. Intraclass correlation coefficient (ICC) was used to estimate the interobserver agreement for ER and PR H-scores on a continuous scale (0–300). There was 100% agreement for categorical ER results (κ = 1) and 97% agreement (κ = 0.823, P < .001) for categorical PR results. For quantitative H-scores, ICC agreement was 0.85 (95% confidence interval [CI] = 0.79–0.90) for ER and 0.87 (95% CI = 0.82–0.92) for PR. Because the H-score provides a continuous measure of tumor hormone receptor content, we suggest universal adoption of this method.
- Published
- 2012
25. The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma
- Author
-
Isil Z. Yildiz-Aktas, David J. Dabbs, Mamatha Chivukula, Rohit Bhargava, Kim McManus, and Kristine L. Cooper
- Subjects
Pathology ,medicine.medical_specialty ,Tissue Fixation ,Receptor, ErbB-2 ,Receptor expression ,Estrogen receptor ,Breast Neoplasms ,Fixatives ,Invasive breast carcinoma ,Formaldehyde ,Progesterone receptor ,medicine ,Biomarkers, Tumor ,Humans ,Prospective Studies ,Receptor ,Prospective cohort study ,Her2 expression ,business.industry ,Carcinoma ,Estrogen Receptor alpha ,General Medicine ,Immunohistochemistry ,Female ,business ,Receptors, Progesterone - Abstract
We studied the impact of 96 hours of formalin fixation on estrogen receptor (ER), progesterone receptor (PR), and HER2 testing by comparing immunohistochemical results from core biopsy specimens fixed under current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines with results for corresponding resection samples fixed for 96 hours. Samples enriched with cases showing weak to moderate receptor expression on core biopsy were included in the study. Cases were scored using ASCO/CAP guidelines. Of the 47 cases, only 1 case (2%) showed a qualitative change in result. However, this change was a positive ER result (H score, 1) on the 96-hour fixed resected sample compared with a negative ER result (H score, 0) for the core biopsy. Minimal changes in semiquantitative H scoring were noted for ER and PR that were likely due to tumor heterogeneity and/or intraobserver variability as the variation occurred in both directions. ER, PR, and HER2 immunohistochemical results should be considered valid for cases fixed up to 96 hours.
- Published
- 2012
26. Risk of malignancy when microscopic radial scars and microscopic papillomas are found at percutaneous biopsy
- Author
-
Neha Desai Choksi, Margarita L. Zuley, Karen A Lee, Mamatha Chivukula, Jules H. Sumkin, and Marie A. Ganott
- Subjects
medicine.medical_specialty ,Vacuum ,Radial scar ,Breast Neoplasms ,Malignancy ,Radiography, Interventional ,Risk Assessment ,Papilloma, Intraductal ,Cicatrix ,Intraductal papilloma ,Pathology Result ,Biopsy ,medicine ,Carcinoma ,Humans ,Radiology, Nuclear Medicine and imaging ,Ultrasonography, Interventional ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Incidence ,Biopsy, Needle ,General Medicine ,Middle Aged ,medicine.disease ,Surgery ,Papilloma ,Histopathology ,Female ,Radiology ,Ultrasonography, Mammary ,business ,Follow-Up Studies ,Mammography - Abstract
The objective of our study was to assess the incidence of associated malignancy when microscopic radial scars and microscopic intraductal papillomas are encountered at percutaneous biopsy for lesions that otherwise reveal benign histopathology.A search of the pathology database for the period from December 14, 2006, through December 21, 2009, identified patients with a microscopic radial scar, a microscopic intraductal papilloma, or both at percutaneous biopsy. Patients whose percutaneous biopsy was performed for a lesion that revealed carcinoma or a high-risk pathology result were excluded to avoid confounding bias, as were patients who had only imaging follow-up. Only patients who underwent surgery solely for the study lesion were included. The lesion type that prompted core biopsy, biopsy guidance and device, sample number, and surgical outcomes were recorded. The incidences of benign, high-risk, and malignant pathology findings from surgery were calculated.The search revealed 35 patients (18 microscopic radial scars, 17 microscopic papillomas) who underwent surgery solely for the study lesion. Stereotactic guidance was used for 15 (43%); ultrasound, for 12 (34%); and MRI, for eight (23%). At surgery, 12 patients (34%) had high-risk histopathology results and 23 (66%) had benign results. No study lesions were upgraded to malignancy.Our study found no evidence of associated malignancy at surgical excision when microscopic radial scars and microscopic intraductal papillomas were encountered at percutaneous biopsy in patients who otherwise had benign histopathology results; thus, routine imaging follow-up may be performed.
- Published
- 2012
27. Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression
- Author
-
Robert P. Edwards, Robert Bowser, Faina Linkov, Ashley S. Felix, Mamatha Chivukula, Anil V. Parwani, Joel L. Weissfeld, and Roslyn A. Stone
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Receptors, CXCR4 ,medicine.drug_class ,Estrogen receptor ,Kaplan-Meier Estimate ,CXCR4 ,Article ,Disease-Free Survival ,Metastasis ,Endometrium ,Internal medicine ,Biomarkers, Tumor ,Medicine ,Humans ,Risk factor ,business.industry ,Endometrial cancer ,medicine.disease ,biological factors ,Chemokine CXCL12 ,Cancer registry ,Endometrial Neoplasms ,Endocrinology ,Treatment Outcome ,Receptors, Estrogen ,Estrogen ,embryonic structures ,Immunohistochemistry ,Female ,biological phenomena, cell phenomena, and immunity ,business - Abstract
CXCL12 is a chemotactic cytokine that has pro-metastatic functions in several malignancies through interactions with its receptor, CXCR4. CXCL12 is an estrogen-regulated gene, and notably, estrogen is a major risk factor for endometrial cancer (EC) development. As few studies examine concurrent CXCL12, CXCR4, and estrogen receptor (ER) expression in EC patients, we examined this pathway in 199 EC patients with data from the University of Pittsburgh Medical Center Cancer Registry. Immunohistochemistry (IHC) was used to detect CXCR4, CXCL12 and ER protein expression. As CXCR4 expression was positive in all cases, this investigation focused on associations between CXCL12 and ER expression, clinicopathologic factors and survival outcomes using chi-square tests, Kaplan-Meier graphs, and log-rank tests. CXCL12 expression was negative in 63 cases (32%) and positive in 136 cases (68%). Negative CXCL12 expression was borderline significantly associated with metastasis (χ(2) p = 0.07). ER expression was negative in 75 cases (38%) and positive in 124 cases (62%). Positive ER expression was significantly associated with low grade and early stage tumors (χ(2) p0.001). CXCL12 and ER were not significantly associated (χ(2) p = 0.11). Positive CXCL12 expression was associated with longer overall survival (OS) (log-rank p = 0.006) and longer recurrence-free survival (RFS) (log-rank p = 0.01) in ER negative patients, but not in ER positive patients. We identified a unique molecular signature associated with better OS and RFS in EC patients. In addition to pathological characteristics of the tumor, expression of CXCL12 and ER may be clinically useful for assigning adjuvant treatment to EC cases.
- Published
- 2012
28. Neoplasia of the Male Breast
- Author
-
Mamatha Chivukula and David J. Dabbs
- Subjects
Oncology ,medicine.medical_specialty ,Breast cancer ,business.industry ,Internal medicine ,medicine ,Male breast ,medicine.disease ,business - Published
- 2012
29. Contributors
- Author
-
D. Craig Allred, Sunil Badve, Frederick L. Baehner, Rohit Bhargava, Werner Boecker, Mamatha Chivukula, Beth Z. Clark, David J. Dabbs, Ian O. Ellis, Nicole N. Esposito, Marie A. Ganott, Felipe C. Geyer, Christiane M. Hakim, Syed A. Hoda, Magali Lacroix-Triki, Shahla Masood, Syed K. Mohsin, Joseph T. Rabban, Emad A. Rakha, Jorge S. Reis-Filho, Christine G. Roth, Reda S. Saad, Sunati Sahoo, Sandra J. Shin, Jan F. Silverman, Najwa Somani, Jules H. Sumkin, Steven H. Swerdlow, Victor G. Vogel, Amy Vogia, Noel Weidner, Britta Weigelt, and Mark R. Wick
- Published
- 2012
30. Limitations of the criteria used to diagnose histologic endometritis in epidemiologic pelvic inflammatory disease research
- Author
-
Harold C. Wiesenfeld, Mamatha Chivukula, Antonio J. Amortegui, Uma Krishnamurti, Jeffrey A. Kant, Jaclyn M. Phillips, Thomas L. Cherpes, Richard L. Sweet, and Rodolfo D. Vicetti Miguel
- Subjects
Adult ,Pathology ,medicine.medical_specialty ,Adolescent ,Neutrophils ,Biopsy ,Plasma Cells ,Plasma cell ,Sensitivity and Specificity ,Article ,Pathology and Forensic Medicine ,Endometrium ,Young Adult ,Predictive Value of Tests ,Pelvic inflammatory disease ,Leukocytes ,Prevalence ,Medicine ,Humans ,medicine.diagnostic_test ,biology ,business.industry ,Antibodies, Monoclonal ,Cell Biology ,medicine.disease ,Flow Cytometry ,Immunohistochemistry ,Epidemiologic Studies ,medicine.anatomical_structure ,Monoclonal ,biology.protein ,Female ,Endometritis ,Syndecan-1 ,Antibody ,business ,Chronic Endometritis ,Endometrial biopsy ,Pelvic Inflammatory Disease - Abstract
While endometrial neutrophils and plasma cells are criteria used to diagnose histologic endometritis in epidemiologic pelvic inflammatory disease (PID) research, plasma cell misidentification and nonspecificity may limit the accuracy of these criteria. Herein, we examined: (1) the identification of endometrial plasma cells with conventional methyl green pyronin-based methodology versus plasma cell-specific (CD138) immunostaining, (2) the prevalence of endometrial plasma cells among women at low risk for PID, and (3) endometrial leukocyte subpopulations among women diagnosed with acute or chronic histologic endometritis by conventional criteria. We observed an absence of CD138+ cells in 25% of endometrial biopsies in which plasma cells had been identified by conventional methodology, while additional immunohistochemical analyses revealed indistinguishable inflammatory infiltrates among women diagnosed with acute or chronic endometritis by conventional criteria. Among women considered at lower risk for PID development, flow cytometric analyses detected plasma cells in 30% of endometrial biopsy specimens, suggesting that these cells, even when accurately identified, only nonspecifically identify upper genital tract inflammatory processes. Combined, our findings underscore the limitations of the criteria used to diagnose histologic endometritis in PID-related research and suggest that satisfactory understanding of PID pathogenesis, treatment, and prevention is hindered by continued use of these criteria.
- Published
- 2011
31. Pleomorphic lobular carcinoma in situ: A divergent entity with emerging significance
- Author
-
Mamatha, Chivukula
- Subjects
Carcinoma, Lobular ,Humans ,Breast Neoplasms ,Female ,Carcinoma in Situ - Published
- 2011
32. Immunocytology
- Author
-
David J. Dabbs and Mamatha Chivukula
- Subjects
business.industry ,Medicine ,business - Published
- 2011
33. Rate of detection of high-risk HPV with two assays in women ≥ 30 years of age
- Author
-
Nicholas T. Potter, Neil B. Quigley, Marilyn C. Olson, James R. Welch, Mamatha Chivukula, and Mirna Z. Knight
- Subjects
Adult ,medicine.medical_specialty ,Population ,Cytological Techniques ,Prevalence ,Uterine Cervical Neoplasms ,Alphapapillomavirus ,Virology ,Cytology ,medicine ,Humans ,Mass Screening ,Human papillomavirus ,education ,Aged ,Gynecology ,education.field_of_study ,Obstetrics ,business.industry ,Diagnostic Tests, Routine ,Hybrid capture ,Papillomavirus Infections ,virus diseases ,Middle Aged ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Confidence interval ,Infectious Diseases ,High risk hpv ,Female ,business ,Ascus - Abstract
Background High-risk (HR) human papillomavirus (HPV) prevalence rates, as determined by the Cervista ® HPV HR test, in women aged ≥30 years in a routine screening population have not been studied. Objectives The primary objective of this study was to estimate HR HPV prevalence in women negative for intraepithelial lesion or malignancy (NILM) cytology using the CERVISTA HPV HR test. The study also compared HR HPV prevalence rates in women aged ≥30 years and NILM cytology using the CERVISTA HPV HR and Hybrid Capture ® 2 (hc2) tests. Study design A multi-center study was conducted to analyze HR HPV prevalence rates using the CERVISTA HPV HR test from residual ThinPrep ® specimens. HR HPV positive rates were determined for hc2; percent agreement between the CERVISTA HPV HR and the hc2 tests were reported. Results HR HPV prevalence rates among women with NILM cytology were not statistically different between the CERVISTA HPV HR and hc2 tests (6.92% [98/1417] versus 5.93% [84/1417], respectively; P > 0.05). The overall percent agreement between the tests was 95.3% (1351/1417; 95% confidence interval [CI]: 94.1–96.3; κ = 0.61, 95% CI: 0.53–0.70). There were no statistically significant differences between tests across age groups or investigational sites. For both tests, there was a statistically significant decrease in HR HPV positive results as age increases (CERVISTA HPV HR, P = 0.0009; hc2, P Discussion There is no statistically significant difference between HR HPV prevalence rates obtained with the CERVISTA HPV HR and hc2 tests in women aged ≥30 years with NILM cytology.
- Published
- 2010
34. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer
- Author
-
Koichi Sakakura, David S. Hsu, Thaer Khoury, Adam Brufsky, Soldano Ferrone, Akihiro Katayama, H. Kim Lyerly, Takuya Osada, Xinhui Wang, James B. McCarthy, Timothy M. Clay, Mamatha Chivukula, Ling Yu, Yangyang Wang, and William T. Barry
- Subjects
Cancer Research ,Lung Neoplasms ,medicine.drug_class ,Cell Survival ,medicine.medical_treatment ,Immunoblotting ,Transplantation, Heterologous ,Antineoplastic Agents ,Apoptosis ,Breast Neoplasms ,Biology ,Monoclonal antibody ,Mice ,Breast cancer ,Cell Movement ,Cell Line, Tumor ,medicine ,Biomarkers, Tumor ,Animals ,Humans ,Chondroitin Sulfate Proteoglycan 4 ,Melanoma ,Triple-negative breast cancer ,Aged ,Cell Proliferation ,Reverse Transcriptase Polymerase Chain Reaction ,Cancer ,Antibodies, Monoclonal ,Membrane Proteins ,Confounding Factors, Epidemiologic ,Immunotherapy ,Articles ,medicine.disease ,Flow Cytometry ,Pleural Effusion ,Disease Models, Animal ,Oncology ,Chondroitin Sulfate Proteoglycans ,CSPG4 ,Immunology ,Cancer research ,Female ,Breast disease ,Signal Transduction - Abstract
The cell surface proteoglycan, chondroitin sulfate proteoglycan 4 (CSPG4), is a potential target for monoclonal antibody (mAb)-based immunotherapy for many types of cancer. The lack of effective therapy for triple-negative breast cancer (TNBC) prompted us to examine whether CSPG4 is expressed in TNBC and can be targeted with CSPG4-specific mAb.CSPG4 protein expression was assessed in 44 primary TNBC lesions, in TNBC cell lines HS578T, MDA-MB-231, MDA-MB-435, and SUM149, and in tumor cells in pleural effusions from 12 metastatic breast cancer patients. The effect of CSPG4-specific mAb 225.28 on growth, adhesion, and migration of TNBC cells was tested in vitro. The ability of mAb 225.28 to induce regression of tumor metastases (n = 7 mice) and to inhibit spontaneous metastasis and tumor recurrence (n = 12 mice per group) was tested in breast cancer models in mice. The mechanisms responsible for the antitumor effect of mAb 225.28 were also investigated in the cell lines and in the mouse models. All statistical tests were two-sided.CSPG4 protein was preferentially expressed in 32 of the 44 (72.7%) primary TNBC lesions tested, in TNBC cell lines, and in tumor cells in pleural effusions from 12 metastatic breast cancer patients. CSPG4-specific mAb 225.28 statistically significantly inhibited growth, adhesion, and migration of TNBC cells in vitro. mAb 225.28 induced 73.1% regression of tumor metastasis in a TNBC cell-derived experimental lung metastasis model (mAb 225.28 vs control, mean area of metastatic nodules = 44590.8 vs 165950.8 μm(2); difference of mean = 121360.0 μm(2), 95% confidence interval = 91010.7 to 151709.4 μm(2); P.001). Additionally, mAb 225.28 statistically significantly reduced spontaneous lung metastases and tumor recurrences in an orthotopic xenograft mouse model. The mechanisms responsible for antitumor effect included increased apoptosis and reduced mitotic activity in tumor cells, decreased blood vessel density in the tumor microenvironment, and reduced activation of signaling pathways involved in cell survival, proliferation and metastasis.This study identified CSPG4 as a new target for TNBC. The antitumor activity of CSPG4-specific mAb was mediated by multiple mechanisms, including the inhibition of signaling pathways crucial for TNBC cell survival, proliferation, and metastasis.
- Published
- 2010
35. Clinical importance of histologic grading of lobular carcinoma in situ in breast core needle biopsy specimens: current issues and controversies
- Author
-
Gloria Carter, George C. Tseng, Mamatha Chivukula, and Faye F. Gao
- Subjects
medicine.medical_specialty ,Pathology ,Neoplasm, Residual ,Lobular carcinoma ,Mammary gland ,Breast Neoplasms ,Biopsy ,medicine ,Humans ,Mammary Glands, Human ,Cell Nucleus ,Hyperplasia ,medicine.diagnostic_test ,business.industry ,Carcinoma in situ ,Biopsy, Needle ,Carcinoma, Ductal, Breast ,Anatomical pathology ,Neoplasms, Second Primary ,General Medicine ,Ductal carcinoma ,medicine.disease ,Prognosis ,Atypical Ductal Breast Hyperplasia ,Carcinoma, Lobular ,medicine.anatomical_structure ,Carcinoma, Intraductal, Noninfiltrating ,Pleomorphism (microbiology) ,Female ,business ,Carcinoma in Situ ,Follow-Up Studies - Abstract
Lobular carcinoma in situ (LCIS) is considered a risk factor for development of invasive carcinoma (IC). Many variants of LCIS have been described based on pathologic features such as nuclear grade, pleomorphism, and necrosis, but little is known about the biology of these variants. The proposed 3-tier grading system for LCIS has not been validated or endorsed across laboratories. We found significant upstaging of pure pleomorphic LCIS (LCIS with nuclear grade [NG] 3), up to 25% in core needle biopsy (CNB) specimens, in an earlier study. The aim of the current study was to address the importance of pure classical LCIS (NGs 1 and 2) in CNB specimens along with clinicopathologic follow-up. In follow-up resection specimens, IC or ductal carcinoma in situ was seen in 18% (7/39), a high incidence of residual LCIS was seen in 69% (27/39), and other high-risk lesions, such as atypical ductal hyperplasia, were seen in 36% (14/39) of LCIS NG 2 cases. Our study illustrates the importance of grading LCIS; we recommend follow-up excision in LCIS NG 2 cases owing to a high incidence of residual LCIS and the likelihood of identifying other high-risk lesions.
- Published
- 2010
36. Factors associated with Type I and Type II endometrial cancer
- Author
-
Robert P. Edwards, Mamatha Chivukula, Robert Bowser, Ashley S. Felix, Joel L. Weissfeld, Roslyn A. Stone, and Faina Linkov
- Subjects
Cancer Research ,medicine.medical_specialty ,Logistic regression ,Malignancy ,Article ,Body Mass Index ,Cohort Studies ,Pregnancy ,Risk Factors ,Internal medicine ,Epidemiology ,medicine ,Humans ,Obesity ,Retrospective Studies ,Gynecology ,business.industry ,Endometrial cancer ,Racial Groups ,Age Factors ,Retrospective cohort study ,Neoplasms, Second Primary ,medicine.disease ,Cancer registry ,Endometrial Neoplasms ,Parity ,Logistic Models ,Oncology ,Female ,business ,Body mass index ,Cohort study - Abstract
We investigated risk factors for Type II (n = 176) vs. Type I (n = 1,576) endometrial cancer (EC) in cases treated at Magee-Womens Hospital between 1996 and 2008. Clinical data were available from the University of Pittsburgh Medical Center (UPMC) Network Cancer Registry. Logistic regression was used to estimate the adjusted odds of having Type II EC vs. Type I EC. Risk factors of interest in this analysis were age, race, body mass index (BMI), year of diagnosis, parity, menopausal status, and history of additional primary tumors. Relative to women with Type I EC, women with Type II EC were more likely to be older at diagnosis (OR: 1.03 per 1 year increase in age, 95% CI 1.01–1.05), of non-white race (OR: 2.95, 95% CI 1.66–5.27), have a history of additional primary tumors (OR: 1.56, 95% CI 1.05–2.32), and less likely to be obese (OR: 0.45, 95% CI 0.29–0.70). In this large retrospective cohort of patients with EC, the striking difference in risk factors associated with Type II vs. Type I tumors suggests that these subtypes represent different disease entities that require different treatment modalities. Currently, Type II cases have a significantly worse prognosis compared to Type I. Further characterization of risk factors associated with developing Type II tumors is needed to prevent this aggressive malignancy.
- Published
- 2010
37. CONTRIBUTORS
- Author
-
N. Volkan Adsay, Nancy J. Barr, Olca Basturk, Parul Bhargava, Rohit Bhargava, Mamatha Chivukula, Cheryl M. Coffin, Jessica M. Comstock, David J. Dabbs, Sanja Dacic, Ronald A. DeLellis, Jonathan I. Epstein, Nicole N. Esposito, Eduardo J. Ezyaguirre, Alton B. Farris III, Jeffrey D. Goldsmith, Samuel P. Hammar, Jason L. Hornick, Jennifer L. Hunt, Marshall E. Kadin, Alyssa M. Krasinskas, Alvin W. Martin, Paul E. McKeever, George J. Netto, Yuri E. Nikiforov, Marina N. Nikiforova, James W. Patterson, Joseph T. Rabban, Shan-Rong Shi, Sandra J. Shin, Robert A. Soslow, Paul E. Swanson, Clive R. Taylor, Diana O. Treaba, David H. Walker, Jeremy C. Wallentine, Mark R. Wick, Sherif R. Zaki, and Charles Z. Zaloudek
- Published
- 2010
38. Clinicopathologic implications of 'flat epithelial atypia' in core needle biopsy specimens of the breast
- Author
-
David J. Dabbs, Mamatha Chivukula, Rohit Bhargava, and George C. Tseng
- Subjects
Adult ,medicine.medical_specialty ,Pathology ,Breast Neoplasms ,Biopsy ,medicine ,Humans ,Clinical significance ,Aged ,Aged, 80 and over ,Hyperplasia ,medicine.diagnostic_test ,business.industry ,Carcinoma in situ ,Biopsy, Needle ,Anatomical pathology ,General Medicine ,Ductal carcinoma ,Middle Aged ,medicine.disease ,Prognosis ,Atypical Ductal Breast Hyperplasia ,Histopathology ,Female ,business ,Precancerous Conditions - Abstract
Flat epithelial atypia (FEA) is an emerging entity of uncertain clinical significance, and outcome data are sparse. The aim of this study was to evaluate the clinicopathologic significance of this entity for proper management. All core needle biopsy (CNB) specimens diagnosed as atypical ductal hyperplasia (ADH) from January 2006 to April 2008 were retrieved. H&E-stained slides of 5 levels on each case were reviewed. The differences in upstaging in subsequent excisions in the FEA and ADH group (31/189 [16.4%]) vs the pure FEA group (5/35 [14%]) and pure FEA (5/35 [14%]) vs pure ADH (5/45 [11%]) were not statistically significant. We observed that FEA evolved into ADH at the same site at an average of 3 to 4 levels. Our study concludes that there is an association of FEA with ADH on multiple levels of CNB specimens, and follow-up surgical excision findings for FEA are clinically significant.
- Published
- 2009
39. Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications
- Author
-
David J. Dabbs, George C. Tseng, Gloria Carter, Mamatha Chivukula, and Akosua Domfeh
- Subjects
Pathology ,medicine.medical_specialty ,Histology ,Breast Neoplasms ,Mastitis ,Pathology and Forensic Medicine ,Lymphocytic Infiltrate ,Diagnosis, Differential ,Papilloma, Intraductal ,Breast cancer ,Lymphocytes, Tumor-Infiltrating ,medicine ,Carcinoma ,Biomarkers, Tumor ,Animals ,Humans ,Neoplasm Metastasis ,business.industry ,Melanoma ,Myoepithelial cell ,Ductal carcinoma ,medicine.disease ,Prognosis ,Medical Laboratory Technology ,Carcinoma, Intraductal, Noninfiltrating ,Cell Transformation, Neoplastic ,Papilloma ,Female ,Differential diagnosis ,Neoplasm Recurrence, Local ,business - Abstract
Regressive changes (RC) have been described in malignant melanoma, carcinomas of the prostate and cervix. The presence of RC in these neoplasms may signify some degree of host response to tumor and seems to be a sign of poor prognosis for some neoplasms. RC in breast cancer is vaguely defined in the older literature. We have observed periodically similar RC in a subset of high-grade ductal carcinoma in situ (HGDCIS) in breast specimens. The aim of our study is to demonstrate how to recognize RC in the diagnostic setting and an attempt to understand the biologic behavior in this subset of HGDCIS cases. Fifty-nine cases of HG-DCIS (35 cases with RC and 24 cases without RC) were included. We defined RC in our study as demonstrating thick periductal fibrosis, dense lymphocytic infiltrate, and a thin rim of intact neoplastic cells. A short panel of immunomarkers to study this entity included myoepithelial markers. Reduced expression of myoepithelial markers (p63 and smooth muscle heavy chain myosin) were seen more frequently in the HGDCIS group with RC than without RC cases. Invasion as well as metastatic disease was seen in association with HGDCIS with RC nearly 4 times as often. It is also critically important to recognize HGDCIS-RC for diagnostic purposes, as the differential diagnosis of RC includes, benign associations such as papilloma, fibrocystic changes and periductal mastitis. HGDCIS-RC may also be a sign of an aggressive phenotype than other HGDCIS subtypes. Further outcome studies are necessary to determine if it has a clinical impact akin to other tumors with RC.
- Published
- 2009
40. Immunocytochemistry
- Author
-
David J. Dabbs and Mamatha Chivukula
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Immunocytochemistry ,Medicine ,business - Published
- 2008
41. Contributors
- Author
-
Fadi W. Abdul-Karim, Tahseen Al-Saleem, Anniek J.M. van Aspert – van Erp, Peter H. Bartels, Simon Bergman, Marluce Bibbo, Sandra H. Bigner, Lukas Bubendorf, Johan Bulten, Alicia L. Carter, Mamatha Chivukula, Luiz M. Collaço, Terence J. Colgan, David J. Dabbs, Magnus von Knebel Doeberitz, Craig E. Elson, Michael S. Facik, Brendan T. Fitzpatrick, William J. Frable, Hugo Galera-Davidson, Kim R. Geisinger, Ben J. Glasgow, Katharina Glatz-Krieger, Ricardo González-Cámpora, Hans Jurgen Grote, Prabodh K. Gupta, Pierre Heimann, William W. Johnston, Ruth L. Katz, Catherine M. Keebler, William H. Kern, Larry F. Kluskens, Savitri Krishnamurthy, Oscar Lin, Diane B. Mandell, Cindy McGrath, C. Meg McLachlin, Christopher R.B. Merritt, Kiran F. Narsinh, Joseph F. Nasuti, Ritu Nayar, Bernard Naylor, Wai-Kuen Ng, José Schalper Perez, Reda S. Saad, Jan F. Silverman, Lambert Skoog, Diane Solomon, Theresa M. Somrak, Kari Syrjanen, Edneia M. Tani, Liang-Che Tao, Alain Verhest, G. Peter Vooijs, Nicolas Wentzensen, David C. Wilbur, Moira D. Wood, Bin Yang, Grace C.H. Yang, Nancy A. Young, Maureen F. Zakowski, and Lucilia Zardo
- Published
- 2008
42. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin
- Author
-
David J. Dabbs, Mamatha Chivukula, and Rohit Bhargava
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Delta Catenin ,animal structures ,Lobular carcinoma ,Mammary gland ,Breast Neoplasms ,Biology ,Pathology and Forensic Medicine ,Diagnosis, Differential ,medicine ,Carcinoma ,Biomarkers, Tumor ,Humans ,skin and connective tissue diseases ,neoplasms ,Tissue microarray ,Reproducibility of Results ,Anatomical pathology ,Catenins ,Ductal carcinoma ,medicine.disease ,Cadherins ,Phosphoproteins ,Immunohistochemistry ,body regions ,Carcinoma, Lobular ,medicine.anatomical_structure ,Carcinoma, Intraductal, Noninfiltrating ,Tissue Array Analysis ,Invasive lobular carcinoma ,Surgery ,Female ,Anatomy ,Cell Adhesion Molecules ,Precancerous Conditions ,Lobular Neoplasia - Abstract
The distinction between lobular and ductal lesions of the breast is important in several circumstances. Diagnostic reproducibility of lobular versus ductal lesions, based on histology alone, is less than optimal. The proper distinction between atypical lobular hyperplasia, lobular carcinoma in situ and low-grade ductal carcinoma in situ is critical for patient management. Patients who have a core biopsy of invasive lobular carcinoma often have preoperative magnetic resonance imaging to prepare the surgeon for proper margin attainment. E-cadherin, a negative membrane marker for lobular neoplasia, is useful in the distinction of lobular versus ductal neoplasia, but as a negative marker, can be difficult to interpret in particularly challenging cases. In this study, we surveyed primary and metastatic ductal lesions (62) and lobular lesions (64) of the breast to determine if P120 catenin is useful in the diagnostic distinction between lobular and ductal neoplasia. Primary breast ductal and lobular preneoplastic and neoplastic lesions were immunostained with E-cadherin and P120ctn and independently classified as ductal or lobular lesions. In addition, a wide array of carcinomas of different types were surveyed with P120ctn in tissue microarrays to ascertain whether the cytoplasmic P120ctn immunostaining pattern observed in lobular neoplasia was unique. Accurate categorization of ductal versus lobular neoplasia in the breast with P120ctn immunostaining was effective in all cases. Separation of low-grade ductal carcinoma in situ from lobular neoplasia was efficient. Diagnostically, P120ctn was particularly useful in identifying early lesions of lobular neoplasia. Of the other tumors that may morphologically mimic lobular carcinoma, only the diffusely infiltrating variants of rectal and gastric carcinomas showed diffuse cytoplasmic P120ctn immunostaining. Caution should be exercised when examining tumors in metastatic sites with P120ctn, with the incorporation of an appropriate panel of immunostains.
- Published
- 2007
43. Prognostic significance of transcription factors FOXA1 and GATA-3 in ductal carcinoma in situ in terms of recurrence and estrogen receptor status
- Author
-
Jennifer Picarsic, Adam Brufsky, Gautam Bulusu, Mamatha Chivukula, Gretchen M. Ahrendt, and Gloria Carter
- Subjects
Oncology ,In situ ,medicine.medical_specialty ,Pathology ,Invasive carcinoma ,Proliferation index ,Estrogen receptor ,Ductal carcinoma ,Biology ,Internal medicine ,medicine ,FOXA1 ,skin and connective tissue diseases ,neoplasms ,Transcription factor ,Estrogen Receptor Status - Abstract
Aim: The aim was to analyze the expression of novel biological transcription markers, forkhead-box A1 (FOXA1), GATA binding protein 3 (GATA-3), and established markers such as Ki-67 (MIB-1) and human epidermal growth factor receptor 2 (HER2) in estrogen receptor (ER(+)) and ER(-) ductal carcinoma in situ (DCIS) patients with/without recurrence. Methods: Two hundred and ninety-one cases of DCIS were retrieved from our pathology database, with complete data available for 219 cases. The follow-up period is from 1988 to 2009. Recurrence is defined in terms of DCIS or invasive carcinoma (IC). No recurrence was seen in 88% (196/219) of cases; 12% (26/219) had a recurrence (IC: 13, DCIS: 13). We are reporting the results of biological marker expression in terms of recurrence and ER status. Results: Our study demonstrates strong expression of GATA-3 in the ER(+) DCIS in recurrence and nonrecurrence groups similar to previously described in IC. A reduced expression of GATA-3 was observed in ER(-) recurrence and nonrecurrence groups. A strong HER2 protein expression, as well as high proliferation index, was seen in recurrence group (DCIS and IC). FOXA1 expression is reduced across the groups though not statistically significant. Conclusion: This is the first study to analyze novel transcription markers FOXA1 and GATA-3 in DCIS. Further work needs to be done on a larger cohort of DCIS cases with recurrence to better understand, which variables are best able to predict recurrence and guide therapy decision strategies. Maintenance of FOXA1 and GATA-3 expression in ER(-) DCIS may offer new promising targets for therapy in future.
- Published
- 2015
44. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study
- Author
-
Mamatha Chivukula, Nicole Nicosia Esposito, and David J. Dabbs
- Subjects
Adult ,Pathology ,medicine.medical_specialty ,Time Factors ,Receptor, ErbB-2 ,Lobular carcinoma ,Breast Neoplasms ,Biology ,Adenocarcinoma ,Pathology and Forensic Medicine ,Metastasis ,Diagnosis, Differential ,Immunophenotyping ,Progesterone receptor ,Carcinoma ,medicine ,Humans ,Neoplasm Invasiveness ,skin and connective tissue diseases ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Carcinoma, Ductal, Breast ,Catenins ,Middle Aged ,medicine.disease ,Cadherins ,Prognosis ,Immunohistochemistry ,Survival Analysis ,Carcinoma, Lobular ,Phenotype ,Receptors, Estrogen ,Catenin ,Keratins ,Female ,Catenin complex ,Lymph Nodes ,Receptors, Progesterone ,Follow-Up Studies - Abstract
Tubulolobular carcinoma is a type of mammary carcinoma that displays an admixture of invasive tubules and lobular-like cells. Previous reports have shown it to share clinical similarities to lobular carcinoma, whereas more recent studies have shown it to be E-cadherin positive. The aim of the current study was to further explore the immunophenotype of tubulolobular carcinoma, and to document its natural behavior. Nineteen cases of tubulolobular carcinoma and 10 cases each of tubular and lobular carcinoma were retrieved for comparison analysis. Immunohistochemistry was performed with antibodies against estrogen receptor, progesterone receptor, HER2/neu, 34betaE12, E-cadherin, and the catenins. Twenty-five percent of patients with tubulolobular carcinoma presented with greater than stage I disease, compared to 0 and 60% of patients with tubular and lobular carcinoma, respectively. Two patients with tubulolobular carcinoma had tumor recurrence, one of whom also developed metastasis. The majority of all carcinomas were estrogen and progesterone receptor positive. E-cadherin displayed membranous staining in all tubular and tubulolobular carcinomas, and was negative in all lobular carcinomas. Half of each carcinoma subtype displayed granular cytoplasmic 34betaE12 immunoreactivity. alpha-Catenin exhibited partial or complete membranous staining in all tubulolobular and tubular carcinomas, and was negative in all lobular carcinomas. beta-Catenin displayed membranous staining in tubulolobular and tubular carcinomas, whereas all lobular carcinomas had coarse cytoplasmic immunoreactivity. p120 and gamma-catenin displayed membranous staining in 100% of tubulolobular and tubular carcinomas and cytoplasmic staining in 100% of lobular carcinomas. Tubulolobular carcinoma of the breast is thus a distinct type of mammary carcinoma that displays both tubular and lobular patterns histologically but displays the membranous E-cadherin/catenin complex characteristic of the ductal immunophenotype. Tubulolobular carcinoma appears to be more aggressive than tubular carcinoma, as 16% of patients had lymph node metastases, although all were alive at a mean follow-up of 40 months.
- Published
- 2006
45. Immunostaining of cytology smears: a comparative study to identify the most suitable method of smear preparation and fixation with reference to commonly used immunomarkers
- Author
-
Richard A. Komorowski, R. Nagarjun Rao, Vinod B. Shidham, Chung-Che Chang, and Mamatha Chivukula
- Subjects
Pathology ,medicine.medical_specialty ,Histology ,Tissue Fixation ,Cytodiagnosis ,Vimentin ,Pathology and Forensic Medicine ,Immunoenzyme Techniques ,Cytology ,Neoplasms ,Progesterone receptor ,Biomarkers, Tumor ,Medicine ,Humans ,Fixation (histology) ,Paraffin Embedding ,biology ,business.industry ,Chromogranin A ,General Medicine ,Staining ,Cytopathology ,biology.protein ,Female ,business ,Immunostaining - Abstract
As an extension of our previous study (Shidham et al., Acta Cytol 2000;44:1015-1022), we evaluated the interference by methods of cytology smear preparation on the immunoreactivity of cytokeratin-7, cytokeratin-20, estrogen receptor, progesterone receptor, chromogranin, synaptophysin, and vimentin. Scrape cytology smears of 34 fresh specimens submitted for intraoperative consultation were studied. They were processed by three different methods--A: wet-fixed in 95% ethanol; B: air-dried saline rehydrated smears fixed in alcoholic formalin; and C: air-dried saline rehydrated smears fixed in 95% ethanol with 5% acetic acid. The intensity scores of immunostaining were estimated semiquantitatively and compared with corresponding formalin-fixed paraffin-embedded tissue sections (FPTS). Except vimentin, all immunomarkers showed higher intensity scores with method A or B than with method C. Vimentin showed the best results with method A. Our results indicate that the immunoreactivity pattern with each immunomarker is affected by the method of cytology smear processing. Most importantly, method C, which is the desired choice for cytomorphological staining, was not suitable for immunostaining.
- Published
- 2003
46. Immunohistochemical comparison of gastrointestinal stromal tumor and solitary fibrous tumor
- Author
-
Mamatha Chivukula, Richard Komorowski, Vinod B. Shidham, R. Nagarjun Rao, and Dilip Gupta
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Solitary fibrous tumor ,Stromal cell ,Fibroma ,Biology ,Pathology and Forensic Medicine ,Diagnosis, Differential ,Stroma ,medicine ,Biomarkers, Tumor ,Humans ,Stromal tumor ,neoplasms ,Aged ,Gastrointestinal Neoplasms ,Aged, 80 and over ,GiST ,General Medicine ,Middle Aged ,medicine.disease ,Immunohistochemistry ,digestive system diseases ,Neoplasm Proteins ,Medical Laboratory Technology ,Female ,Differential diagnosis ,Stromal Cells - Abstract
Context.—The differential diagnosis of gastrointestinal stromal tumors (GIST) and solitary fibrous tumors (SFT) may be a diagnostic challenging because of overlapping clinicopathologic features. Many studies have shown consistent immunoreactivity for CD117 (c-Kit) in GIST. However, only a few studies have evaluated CD117 expression in SFT, and these studies have used an antibody from Santa Cruz Biotechnology. In non-GIST lesions, reactivity with this antibody has been shown to differ from that with a CD117 antibody from Dako Corporation. The immunoreactivity of SFT with the Dako CD117 antibody has not been reported. Conversely, CD99 is a marker for SFT, and its expression in GIST has not been evaluated. Objective.—To study the immunohistochemical profiles of GIST and SFT to evaluate their diagnostic overlap. Design.—We studied the immunoreactivity of 27 unequivocal GIST and 19 unequivocal extra-abdominal SFT for CD117, CD34, CD99, α-smooth muscle actin, vimentin, CD31, S100 protein, and muscle-specific actin. All antibodies, including CD117, were from Dako Corporation. Results.—We found positive immunoreactivity for CD117 in 100% of GIST and none of SFT; for CD34 in 89% of GIST, and 100% of SFT; for CD99 in 89% of GIST and 100% of SFT; for α-smooth muscle actin in 48% of GIST and 31% of SFT; for vimentin in 89% of GIST and 90% of SFT; and for muscle-specific actin in 22% of GIST and none of SFT. None of the GIST or SFT showed immunoreactivity for CD31 and S100 protein. Conclusions.—The major difference between GIST and SFT was strong CD117 immunoexpression in all GIST and an absence of this expression in all SFT. With the exception of muscle-specific actin, the prevalence of immunoreactivity for the markers studied did not differ substantially between these 2 tumors. We conclude that GIST and SFT show distinctly divergent immunoprofiles with respect to CD117 and muscle-specific actin.
- Published
- 2002
47. Evaluation of crystals in formalin-fixed, paraffin-embedded tissue sections for the differential diagnosis of pseudogout, gout, and tumoral calcinosis
- Author
-
Zainab Basir, Vinod B. Shidham, Ganesh Shidham, and Mamatha Chivukula
- Subjects
Pathology ,medicine.medical_specialty ,Tissue Fixation ,Gout ,H&E stain ,Chondrocalcinosis ,Calcium Pyrophosphate ,Stain ,Pathology and Forensic Medicine ,Diagnosis, Differential ,chemistry.chemical_compound ,Formaldehyde ,medicine ,Humans ,Birefringence ,Paraffin Embedding ,Eosin ,Staining and Labeling ,business.industry ,Calcinosis ,medicine.disease ,Staining ,Uric Acid ,Durapatite ,chemistry ,Tumoral calcinosis ,Pseudogout ,business ,Crystallization - Abstract
Hematoxylin-eosin (H&E)-stained sections may not allow proper evaluation of birefringence properties of the crystals in the lesions of pseudogout, gout, and tumoral calcinosis. This study was undertaken to verify the application of a special stain that could facilitate the evaluation of the birefringence properties of these crystals for definitive diagnosis. We evaluated previously described nonaqueous alcoholic eosin staining (NAES) method based on the principle of using alcoholic eosin without hematoxylin and any other aqueous reagents for staining of formalin-fixed, paraffin-embedded tissue sections. Two observers, in a blinded fashion, evaluated the sections stained with routine H&E and NEAS method without the knowledge about clinical diagnosis. All pseudogout (nine sections from seven cases) and gout (eight sections from five cases) lesions demonstrated birefringence in the sections stained with NAES method. H&E-stained sections showing the respective diagnostic histomorphology failed to demonstrate the birefringent crystals by polarizing microscopy in all the eight sections from gout and in seven of nine sections from pseudogout. Only two H&E-stained sections showed scant calcium pyrophosphate dihydrate (CPPD) crystals in pseudogout. None of the three sections from two cases of tumoral calcinosis showed birefringence with either stain. We conclude that CPPD in pseudogout and monosodium urate in gout may not polarize in the routine H&E-stained sections. However, polarizing microscopy of sections stained with NAES method allowed demonstration of CPPD crystals with positive birefringence in pseudogout, MSU crystals with negative birefringence in gout, and calcium hydroxyapatite crystals without birefringence in tumoral calcinosis. Section stained with NAES method is a significantly useful adjunct to the routine H&E stain for proper evaluation of the crystals under polarizing microscope in these lesions.
- Published
- 2001
48. Pathologic quiz case. Crystal deposition disease of the knee joint
- Author
-
Vinod B. Shidham, Ganesh Shidham, and Mamatha Chivukula
- Subjects
Pathology ,medicine.medical_specialty ,Knee Joint ,medicine.medical_treatment ,Chondrocalcinosis ,Pathology and Forensic Medicine ,Gross examination ,Biopsy ,medicine ,Humans ,Aged ,medicine.diagnostic_test ,business.industry ,Soft tissue ,Arthrocentesis ,Calcinosis ,General Medicine ,Anatomy ,medicine.disease ,Medical Laboratory Technology ,Pigmented villonodular synovitis ,Hemosiderin ,Female ,business - Abstract
65-year-old woman presented with recurrent right knee pain. She had experienced similar persistent and debilitating symptoms 8 months earlier. Evaluation of arthrocentesis on 2 separate occasions was unremarkable. This was followed 5 months later by arthroscopy. Magnetic resonance imaging of the right knee showed lowsignal-intensity lesions compatible with pigmented villonodular synovitis. Biopsy was performed. Gross examination revealed red to yellow-brown soft tissue fragments, measuring 7 cm in aggregate. Light microscopic examination of formalin-fixed, paraffin-embedded tissue sections stained with hematoxylin-eosin (H&E), revealed hyperplastic synovium lined by a prominent synovial lining with focal edema and fibrosis (Figure 1). The fragments were edematous with focal fibrosis. Immediately beneath the synovial lining were scattered histiocytes and lymphocytes, with some histiocytes containing yellow-brown hemosiderin pigment. This pigment was also
- Published
- 2001
49. Small Beginnings: Do They Matter? The Importance of Lymphovascular Invasion in Early Breast Cancer
- Author
-
Adam Brufsky, Mamatha Chivukula, and Nancy E. Davidson
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Pathology ,Lymphovascular invasion ,business.industry ,Disease ,Omics ,medicine.disease ,Lymphovascular ,Breast cancer ,Tumor progression ,Internal medicine ,medicine ,Histopathology ,business ,Pathological - Abstract
In the era of tailored therapy, the evaluation of systemic treatment of breast cancer has been increasingly dominated by consideration of biological features of the tumor and the host. Established breast cancer prognostic factors — those that determine natural history of breast cancer — include axillary nodal status, tumor size, histological grade, hormone receptor status, HER-2 expression, and presence of lymphovascular invasion. These factors often inform decisions about whether to use adjuvant systemic therapy. In contrast, predictive markers like expression of estrogen receptor (ER) alpha, progesterone receptor, and HER-2 protein are powerful tools to select certain types of therapy. Techniques to examine a myriad of genomic, transcriptional, or proteomic factors simultaneously, so-called ‘omics, currently dominate this field. In this molecular age, it is important to refl ect on the continuing importance of classic histopathology. One such feature is identifi cation of lymphovascular invasion. Its importance in prognosis was suggested at the 2007 St Gallen consensus conference ( 1 ) when extensive lymphovascular invasion was identifi ed as a factor to identify women with moderate risk as opposed to low risk for recurrence. These classic histological studies have been amplifi ed by immunohistochemical analysis. For example, immunohistochemical studies of microvascular density assessed by vascular markers such as CD31 and CD34 antigens have usually shown an association between extent of staining and a greater likelihood of subsequent metastatic disease ( 2 ), shorter relapse-free interval, and reduced overall survival in patients with node-negative, ER-negative breast cancers ( 3 ). The presence of tumor in peritumoral small lymphatic spaces, independent of lymphovascular density, has been shown to play a fundamental role in tumor progression ( 4 ). D2-40 or podoplanin, a novel antibody, selectively stains the endothelium of lymphatic vessels. The utility of this antibody as a specifi c marker for detection of lymphovascular invasion in the routine pathological workup is evolving ( 5 , 6 ). Recent studies ( 7 , 8 ) have demonstrated a higher sensitivity for detection of lymphovascular invasion by D2-40 than by routine histological detection or CD31detected vascular invasion. Controversy continues to exist with regard to the process whereby tumor cells gain access via preexisting lymphatics or via newly formed lymphatics at the invasive front of the tumor; D2-40 – detected lymph channel invasion along with high CD31 microvessel density has been associated with outcome in breast cancer as shown in univariate and multivariable analyses. Several studies have consistently shown that lymphovascular invasion is an adverse prognostic factor for relapse and survival in node-negative patients in combination with other risk factors such as tumor grade and size and receptor status ( 9 ). The need for prospective research to defi ne its individual role has been raised. In this issue of the Journal, Ejlertsen et al. ( 10 ) report a comprehensive analysis of the prognostic value of lymphovascular invasion in tumors from 15 659 women entered into the Danish Breast Cancer Cooperative Group registry from 1996 to 2002. The goal of the study was to assess whether lymphovascular invasion was a single independent prognostic factor in stratifying early breast cancer patients as low risk vs high risk for recurrence. The presence of lymphovascular invasion was noted in only 15% of tumors. A statistically signifi cant difference in 5-year invasive cancer disease – free interval was seen: 79.5% (95% confi dence interval [CI] = 78.7% to 80.2%) for patients without lymphovascular invasion vs 54.5% (95% CI = 52.4% to 56.6%) for patients with lymphovascular invasion. These differences were mirrored in the overall survival rates of 87.3% (95% CI = 86.7% to 87.8%) and 66.0% (95% CI = 64.1% to 67.9%) in patients without and with lymphovascular invasion, respectively, and they persisted in multivariable analysis. Finally, the study gives the unexpected and somewhat disappointing result that lymphovascular invasion was associated with adverse outcome in patients who are at high risk for recurrence by other recognized prognostic factors but not in those who are at low risk by the same criteria. It is therefore apparently not useful as a means to subdivide the low-risk group, the group in which many clinicians and patients would like assistance. This fi nding is at odds with the 2007 St Gallen consensus recommendations, where extensive lymphovascular invasion was felt to be suffi cient to upstage patients from low risk to moderate risk for recurrence. The strengths of this study are several. It is derived from a population-wide database of virtually all women diagnosed with breast cancer in Denmark over a 7-year period, who were treated according to standard algorithms and whose tumors were analyzed in a prespecifi ed way for multiple factors including lymphovascular invasion. It has shown the expected association between lymphovascular invasion and other poor prognostic features such as with positive nodal status, tumor size greater than 2 cm, ductal histology, grade 2 or 3, ER negativity, and use of adjuvant endocrine therapy and/or chemotherapy ( P < .001 for each). This agreement with other work gives credence to the results of this study. Finally, the test is “low tech” and could theoretically be performed in virtually any diagnostic laboratory , although it does require two things — investment of valuable pathologist time and availability of standardized criteria that are easily reproduced across all pathology laboratories. The limitations of the study are also real. Neither the reproducibility of the determination of lymphovascular invasion nor its extent was documented; rather a dichotomous cutoff of present or absent was used. HER-2 testing was not performed, and the study period preceded the routine use of several contemporary adjuvant
- Published
- 2009
50. Estrogen and Progesterone Receptors in Breast Carcinoma: Quantitation is Therapeutically Important
- Author
-
Mamatha Chivukula, David J. Dabbs, Rohit Bhargava, and Sushil Beriwal
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,medicine.drug_class ,Estrogen receptor ,Pathology and Forensic Medicine ,Estrogen ,Internal medicine ,Progesterone receptor ,Cancer research ,Medicine ,Anatomy ,business ,Receptor ,Breast carcinoma - Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.